International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 355-360 , 1 February 2010

Local Control Following Permanent Prostate Brachytherapy: Effect of High Biologically Effective Dose on Biopsy Results and Oncologic Outcomes

Presented at the ASTRO meeting, 2008.

  • Nelson N. Stone, M.D.

      Affiliations

    • Department of Urology, Mount Sinai School of Medicine, New York, New York
    • Corresponding Author InformationReprint requests to: Nelson N. Stone, M.D., 21 Timber Trail, Suffern, NY 10901. Tel: (212) 535-0755; Fax: (845) 362-8561
    • ,
  • Richard G. Stock, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Jamie A. Cesaretti, M.D.

      Affiliations

    • Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York
    • ,
  • Pam Unger, M.D.

      Affiliations

    • Department of Pathology, Mount Sinai School of Medicine, New York, New York

Received 25 November 2008 ,Revised 20 January 2009 ,Accepted 29 January 2009.

References 

  1. Stone NN, Stock RG, Unger P. Intermediate-term biochemical and local control following I-125 brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  2. Stock RG, Cahlon O, Cesaretti J, et al. Combined modality treatment in the management of high risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004;59:1352–1359
  3. Cox JD, Grignon DJ, Kaplan RS. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  4. Kuban DA, Levy LB, Potters L, et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:1487–1493
  5. Stone NN, Potters L, Davis BJ, et al. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys. 2007;69:1472–1477
  6. Potters L, Cao Y, Calugaru E, et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001;50:605–614
  7. Stock RG, Stone NN, Cesaretti J, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsies. Int J Radiat Oncol Biol Phys. 2006;64:527–533
  8. Linzer DG, Stock RG, Stone NN, et al. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology. 1996;48:757–761
  9. Stone NN, Stock RG, Parikh D, et al. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. J Urol. 1998;160:1722–1726
  10. Ho AY, Burri RJ, Jennings GT, et al. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined (103)Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy. 2007;6:38–43
  11. Cesaretti JA, Stone NN, Skouteris VM, et al. Brachytherapy for the treatment of prostate cancer. Cancer J. 2007;13:302–312
  12. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  13. Zelefsky MJ, Reuter VE, Fuks Z, et al. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol. 2008;179:1368–1373
  14. Kupelian PA, Ciezki J, Reddy CA, et al. Effect of increasing radiation doses on local and distant failures in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71:16–22
  15. Stone NN, Stock RG, White I, Unger P. Patterns of local failure following prostate brachytherapy. J Urol. 2007;177:1759–1764
  16. Swanson JP, Hussey MA, Tangen CM, et al. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007;25:2225–2229
  17. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  18. Crook J, Malone S, Perry G, et al. Postradiotheryapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355–367
  19. Zapatero A, Mınguez R, Nieto S, et al. Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: What can they teach us?. Eur Urol. 2008;55:902–910
  20. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys. 1995;32:219–225
  21. Stock RG, Stone NN, Lo YC, et al. Post-implant dosimetry for I-125 prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys. 2000;48:899–906
  22. Stone NN, Hong S, Lo YC, et al. Comparison of intraoperative dosimetric implant representation to post-implant dosimetry in patients receiving prostate brachytherapy. Brachytherapy. 2003;2:17–25
  23. Kao J, Stone NN, Lavaf A, et al. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys. 2008;70:96–101

 Conflict of interest: Dr. Stone has ownership interest in Prologics LLC.

PII: S0360-3016(09)00339-3

doi: 10.1016/j.ijrobp.2009.01.078

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 355-360 , 1 February 2010

Article Tools

* Image Usage & Resolution